A Comparative Review of Pharmacoeconomic (PE) Guidelines in ASIA-Pacific (APAC) with Europe and North America


Shah R1, Kalsey MS1, Verma A2, Gautam R1, Prasanna R3
1EVERSANA, Mumbai, India, 2EVERSANA, Mumbai, MH, India, 3EVERSANA, Bangalore, KA, India

Presentation Documents

OBJECTIVE: Globally, PE guidelines are followed to assist in optimization of costs and effectiveness of new health technologies to maximize health benefits. We aimed to compare PE guidelines in APAC countries with that in Europe, Canada, and US region (Group-1).

METHODS: We searched PE guidelines for 13 selected APAC countries (China, Japan, Malaysia, South Korea [SK], Iran, Israel, Thailand, Indonesia, Australia, Philippines, Singapore, Taiwan, and India), US, Canada, and Europe using PubMed, ISPOR website, EUNetHTA guideline, and country-specific websites. The retrieved PE guidelines were analyzed and compared for following major parameters: (P1) economic modeling, (P2) systematic review of evidence, (P3) preference for effectiveness versus efficacy, (P4) total cost versus effectiveness (cost/effectiveness ratio) and (P5) portability of results.

RESULTS: PE guidelines of most APAC countries are consistent with that of Group-1, with few differences observed. P1 is a requirement for most APAC countries except SK and is in alignment with Group-1. P2 is a requirement for most APAC countries as well as Group-1. However, it is only recommended for Taiwan and not stated in PE guidelines of SK. P3 is not stated in PE guidelines for Japan, Malaysia, Israel, and SK, while it is recommended in Group-1. P4 is a requirement for most APAC countries PE guidelines; however, is not stated in Japan, SK, and Israel. P5 is not stated as a requirement for Japan, Malaysia, and SK; in contrary, it is required for Group-1 PE guidelines. Except for Australia which has a well-established HTA, most APAC countries have less established systems, while it is in development phase in India.

CONCLUSION: PE guidelines of APAC countries are fairly in alignment with that of US, Canada, and Europe. The adoption of HTA system in APAC countries has been slow, and its full potential in healthcare decision-making yet to be evaluated.

Conference/Value in Health Info

2022-05, ISPOR 2022, Washington, DC, USA

Value in Health, Volume 25, Issue 6, S1 (June 2022)




Health Technology Assessment, Study Approaches

Topic Subcategory

Literature Review & Synthesis, Systems & Structure


No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now